Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Vericel Corp. (VCEL)

Add VCEL Price Alert      Hide Sticky   Hide Intro
Moderator: lasers
Search This Board: 
Last Post: 7/26/2017 10:52:13 AM - Followers: 151 - Board type: Free - Posts Today: 2

Vericel Corporation. (VCEL)




Acquisition of Sanofi’s CTRM Business
On May 30, 2014, we completed the acquisition of the Cell Therapy and Regenerative Medicine (CTRM) business of Sanofi, a French  société anonyme  (Sanofi), certain assets, including all of the outstanding equity interests of Genzyme Biosurgery ApS (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over 250 patents and patent applications of Sanofi and certain of its subsidiaries, and assumed certain liabilities for purposes of acquiring the portion of the CTRM business, which researches, develops, manufactures, markets and sells Carticel, MACI and Epicel.
We believe that our acquired CTRM business has been a pioneer in the development and commercialization of autologous cell therapies. The CTRM portfolio includes three autologous cell therapy products: Carticel (autologous cultured chondrocytes), a first-generation product for autologous chondrocyte implantation (ACI) currently marketed in the U.S., Epicel (cultured epidermal autografts), a permanent skin replacement for full thickness burns in adults and pediatrics with greater than or equal to 30% of TBSA, also currently marketed in the U.S, and MACI (matrix-applied characterized autologous cultured chondrocytes), a third-generation ACI product approved in Europe and for which a Biologics License Application (BLA) is under review by the FDA. Our product candidate portfolio also includes ixmyelocel-T, a patient-specific multicellular therapy currently in development for the treatment of advanced heart failure due to ischemic DCM.




                                                                      Click on Yellow to REVIEW FDA WEBSITE APPROVING MACI


Interesting FDA Transcript discussions on MACI going forward for widened age bracket and other body joints. 
                                                                                                                                      CLICK ON THE ABOVE LINK



 Our preapproval stage portfolio includes ixmyelocel-T, a unique patient-specific multicellular therapy derived from an adult patient’s own bone marrow which utilizes our proprietary, highly automated and scalable manufacturing system. Our proprietary cell manufacturing process significantly expands the mesenchymal stromal cells (MSCs) and M2-like anti-inflammatory macrophages in the patient’s bone marrow mononuclear cells while retaining many of the hematopoietic cells. These cell types are known to regulate the immune response and play a key role in tissue repair and regeneration by resolving pathologic inflammation, promoting angiogenesis, and remodeling ischemic tissue. The novelty and advantage of using ixmyelocel-T is the expansion of a unique combination of cell populations, including MSCs and M2-like macrophages, which secrete a distinct combination of angiogenic and regenerative factors, and possess the ability to remain anti-inflammatory in the face of inflammatory challenge.

Our lead clinical development program for ixmyelocel-T is focused on severe, chronic ischemic cardiovascular diseases. We have completed the double-blind portion of the Phase 2b ixCELL-DCM study, which is a randomized, double-blind, placebo-controlled clinical trial for patients with advanced heart failure due to ischemic DCM. Ixmyelocel-T has been granted a U.S. Orphan Drug designation by the FDA for the treatment of DCM. We also have conducted clinical studies for the treatment of critical limb ischemia and the treatment of craniofacial defects.
The Phase 2b ixCELL-DCM clinical study treated 114 patients at 28 sites in the U.S. and Canada. We completed enrolling and treating patients in February, 2015. Patients were followed for 12 months for the primary efficacy endpoint of major adverse cardiovascular events, defined as all-cause deaths, all-cause hospitalizations, and unplanned outpatient or emergency department visits for IV treatment of acute worsening heart failure. Secondary endpoints include clinical, functional, structural, symptomatic, quality of life, and biomarker measures at 3, 6 and 9 months. On March 10, 2016, we announced the trial had met its primary endpoint of reduction in clinical cardiac events, and that the full data results from the ixCELL-DCM trial were presented at the Late-Breaking Clinical Trial Sessions of the American College of Cardiology 65 th Annual Scientific Session & Expo on April 4, 2016. On April 4, 2016, we announced that incidence of adverse events, including serious adverse events, in patients treated with ixmyelocel-T was comparable to or lower than patients in the placebo group.  With respect to the secondary endpoints of the trial, the components of the primary endpoint were also analyzed using the Win ratio in a hierarchical manner to incorporate both the incidence and timing of the endpoint components.  The Win ratio result of 1.56 showed that more often ixmyelocel-T was the "winner" in that the time to death, left ventricular assist device placement, heart transplantation or time to cardiovascular hospitalization was shorter for placebo-treated patients, but this difference did not reach statistical significance.  The time to first

Table of Contents
event was longer in the ixmyelocel-T group compared to placebo, but was not statistically significant.  There were no significant structural changes in left ventricle cavity size or left ventricular ejection fraction as measured by echocardiogram in either the ixmyelocel-T or placebo groups.  Both treatment groups had an improvement in the New York Heart Association class and six-minute walk test, with no statistical difference between the groups after 12 months using the last observation carried forward. Because the trial met the primary endpoint, patients who had been assigned to the placebo group or randomized to ixmyelocel-T in the double blind portion of the trial but did not receive ixmyelocel-T will be offered the option to receive treatment.
Future development plans for ixmyelocel-T are dependent upon input from our regulatory interactions and the availability of financing. We are focused on determining the most appropriate manner to fund future development of ixmyelocel-T, balancing risk to the overall business, dilution to current shareholders, and retaining a significant portion of the upside potential of the program for the company and our shareholders.

Ixmyelocel-T for Craniofacial Tissue Engineering

                           Click on above picture to enter another talk/idea zone


About Vericel Corporation:

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant intended to treat cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  Vericel is also developing 2 additional cell products. MACI is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM).

Developing autologous (patient’s own) cell therapies—with integrity
Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient’s own) cells.  In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work.  We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.

                                                                                               CLICK ON ABOVE PICTURE TO SEE NASDAQ.COM SHORT INTEREST

Clinical Research:
Recent News:

Events and Presentations:

Analyst Coverage:


Share Structure:
See Filings

YOU TUBE VIDEOS, and the fourth video down, you will NOW appreciate the meaning of less invasive on the new FDA approved MACI procedure and why MACI is anticipated to be 20x the procedures of Carticel  MUST WATCH

Conference Calls
September 27, 2016 Ladenburg Thalmann
October 24, 2016 Meeting on the Mesa
November 30th, 2016 The 28th Annual Piper Jaffray Healthcare Conference
December 14th, 2016 Vericel Corporation Investor Call

Investor Relations:




 Yummy Land, click on Above Picture


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017 07/26/2017 08:00:00 AM
#6250   hc thxs for all of your work on lasers 07/26/17 10:52:13 AM
#4674  Sticky Note The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in lasers 04/05/16 05:33:01 PM
#6249   Ixmyelocel-T from Vericel is an expanded, multicellular therapy lasers 07/26/17 10:50:54 AM
#6248 me33 07/24/17 06:09:43 PM
#6247   I found a company with old info in hurley cruppers 07/23/17 05:52:32 PM
#6246   BrianIQ posted a nice link on FDA RMAT hurley cruppers 07/23/17 05:46:31 PM
#6245   Those are estimates. Let's see what the company reports. me33 07/18/17 06:39:39 PM
#6244   Now estimated EPS -0,24. Is this company ever manisero66 07/18/17 09:57:37 AM
#6243   8-K events have to be filed timely hurley cruppers 07/16/17 03:17:42 PM
#6242   I expect Ixcell news anytime between now and me33 07/16/17 09:29:59 AM
#6241   Should be some nice news this fall. Hoping silvergun 07/16/17 09:01:47 AM
#6240   Soon. me33 07/15/17 04:05:55 PM
#6239   Any idea on when we hear on X- too simple 07/13/17 07:19:49 PM
#6238   Form CT ORDER Vericel Corp lasers 07/11/17 07:15:56 PM
#6237   BREAKOUT WATCH for possible breakout above 3.52, no resistance realfast95 07/11/17 01:00:33 PM
#6236   Any idea as to when first operations of manisero66 07/08/17 12:03:33 PM
#6235   Perhaps Eastern Capital and Ken Dart 5.5% lasers 06/29/17 12:29:07 PM
#6234   Nice, but looking for over 10 on 03-14-2018 hurley cruppers 06/29/17 10:26:32 AM
#6233   $VCEL on a roll. New HOD $3.50 lasers 06/29/17 10:11:12 AM
#6232   $VCEL Last two sales AHs were combined lasers 06/29/17 06:21:33 AM
#6231   Shake the tree or what is the name Locke1 06/28/17 01:55:54 PM
#6230   $VCEL PreMkt trending higher $3.55 HOD lasers 06/28/17 08:45:31 AM
#6229   Yes IMO $VCEL $10-$20+++ is doable in lasers 06/27/17 09:54:17 AM
#6228   Yes liking great. 3.22 and climbing. Q3 should silvergun 06/27/17 09:44:18 AM
#6227   Simply outstanding actions by $VCEL ixmyelocel-T lasers 06/27/17 06:50:00 AM
#6226   No wonder why the FDA gave fast track hurley cruppers 06/26/17 08:39:39 PM
#6225   Agree. $VCEL on solid footing going forward. lasers 06/26/17 07:59:24 PM
#6224   My eyes on are on MACI quarter 3 hurley cruppers 06/26/17 06:53:31 PM
#6223   $ASTM from the U of Mich and now lasers 06/26/17 06:41:02 PM
#6222   Funny, was just looking at that clinical trial hurley cruppers 06/26/17 05:39:34 PM
#6221   This job is huge lasers 06/26/17 05:27:09 PM
#6220   Most definitely. Nothing remains to be proven. lasers 06/26/17 05:23:06 PM
#6219   So you think X-cell will be approved without realfast95 06/26/17 04:57:29 PM
#6218   hurley cruppers most hearty welcome back. Most lasers 06/26/17 04:04:19 PM
#6217   Been watching the careers on the VCEL site, hurley cruppers 06/26/17 03:30:17 PM
#6216   And that X-cell FDA commercial approval will put hurley cruppers 06/26/17 03:26:34 PM
#6215   That would be up to Dr Scott Gottlieb. lasers 06/26/17 03:12:59 PM
#6214   Nice upswing in volume as well! Lasers, JDBJMB 06/26/17 02:54:11 PM
#6213   More shorting ? or is VCEL finally starting Gremlin3a 06/26/17 02:09:09 PM
#6212   $VCEL new HOD $3.20 lasers 06/26/17 12:58:39 PM
#6211   $VCEL new HOD $3.10 lasers 06/26/17 10:32:17 AM
#6210   COVERAGE INITIATED: Vericel (VCEL) initiated by BTIG Research. lasers 06/21/17 09:00:50 AM
#6209   $VCEL initiated with a new Buy and $6 realfast95 06/20/17 04:23:05 PM
#6208   Why VCEL is a sure thing to go commoncentsinvestor 06/20/17 02:17:48 PM
#6207   MACI Autologous Chondrocyte Implantation Surgical Video - Dr. realfast95 06/13/17 08:30:25 AM
#6206   saw a piece last night on basically taking scubastevemd 06/12/17 04:22:57 PM
#6205   unfriendly short interest realfast95 06/11/17 03:30:11 PM
#6204   The manipulation of VCEL is unbelievable !!! Gremlin3a 06/05/17 10:11:28 AM
#6203   Finally breaking the $3.00 barrier again! lasers 06/01/17 06:25:52 PM
#6202   $3.05 premarket. Fingers crossed. joemont 06/01/17 08:53:05 AM
#6201   From Europe as well as Asia. lasers 05/27/17 01:35:32 PM